Emerging Technologies in Biopharmaceutical Quality Control and Assurance

Mona Das*

Department of Biotechnology, Universitas Pendidikan Indonesia, Indonesia

Abstract

The biopharmaceutical industry is undergoing a transformative phase driven by emerging technologies that • i^* } i_a , & a_b ; i_b ;

Ú^}åiåi\æ}ÁQ}å[}^•iæÊÁQ}å[}^<ir>

Received: $FFER^{E} = 0$ $FER^{E} = 0$ F

Ke od: CleRolfreg, HOUNE Frites, CME tabelon Free Cell Culture

Copyright: $\bigcirc \subseteq \subseteq I \land M$ on a DÉAV@i*Åi*Åæ $\land A$ \land

Emerging technologies are transforming the landscape of biopharmaceutical quality control and assurance. ese advancements are driven by the need for more e cient, accurate, and realtime monitoring and analysis of biopharmaceutical products [2]. Innovations such as advanced analytical techniques, arti cial intelligence, machine learning, automation, and blockchain technology are revolutionizing how quality is assessed and maintained throughout the biopharmaceutical lifecycle. ese technologies o er the potential to enhance product quality, reduce costs, increase regulatory compliance [3], and ultimately ensure that patients receive the safest and most e ective therapies available.

is introduction explores the evolving role of emerging technologies in biopharmaceutical quality control and assurance, highlighting their potential to address current challenges and improve industry standards. By examining the latest advancements and their applications, we can gain a deeper understanding of how these technologies are shaping the future of biopharmaceutical quality management [4].

Di c ion

AI algorithms can analyze vast amounts of data from various sources, identifying patterns and predicting potential quality issues before they arise. ese technologies are used for predictive analytics [8], anomaly